Why AI is the missing piece in amyloid PET imaging for Alzheimer's
Anti-amyloid therapies have made PET central to Alzheimer's care, but neurodegeneration staging is still missing from most workflows. Dual-phase amyloid PET offers a fix, if the noise problem in short acquisitions can be solved. New research shows how deep learning denoising gets there.
What's inside
Growing demand but shrinking headroom
Anti-amyloid therapy approvals have made amyloid PET a clinical prerequisite, with demand projected to grow up to 20-fold. Departments are expected to scan more patients, more often, while waiting lists are already long and scanner capacity hasn't changed.
One injection, two clinical answers
A single amyloid tracer injection can capture both amyloid burden and cerebral perfusion, potentially replacing a separate FDG-PET scan altogether. Fewer sessions per patient means more capacity for the next one, without adding infrastructure or cost.
Shorter scans that don't compromise the read
The barrier to dual-phase protocols is the image quality at short acquisition times. Deep learning denoising removes that barrier, recovering diagnostic confidence from 3-minute early-phase acquisitions and enabling leaner late-phase protocols that free scanner time and reduce tracer use.
.png)
